Nasdaq · CIK 0001590750
VRDN Viridian Therapeutics, Inc.\DE
Insider trading from SEC Form 4. Last filing Jul 2, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Signals
Open-market buys and sells at Viridian Therapeutics, Inc.\DE, scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 16 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 1, 2025 | Jeffrey Robert Ajer director | AGrant or award Stock Option (Right to Buy)derivative | +21,000 | $0.00 | $0 | 21,000 | Jul 2, 2025 |
| Jul 1, 2025 | Christopher W. Cain director | AGrant or award Stock Option (Right to Buy)derivativeindirect: See Footnote | +21,000 | $0.00 | $0 | 21,000 | Jul 2, 2025 |
| Jul 1, 2025 | Sarah Gheuens director | AGrant or award Stock Option (Right to Buy)derivative | +21,000 | $0.00 | $0 | 21,000 | Jul 2, 2025 |
| Jul 1, 2025 | Tomas Kiselak director | AGrant or award Stock Option (Right to Buy)derivativeindirect: See Footnote | +21,000 | $0.00 | $0 | 21,000 | Jul 2, 2025 |
| Jul 1, 2025 | Arlene Morris director | AGrant or award Stock Option (Right to Buy)derivative | +21,000 | $0.00 | $0 | 21,000 | Jul 2, 2025 |
| Jul 1, 2025 | Jennifer K. Moses director | AGrant or award Stock Option (Right to Buy)derivative | +21,000 | $0.00 | $0 | 21,000 | Jul 2, 2025 |
| Jun 9, 2025 | Fairmount Funds Management LLC director, owner | MOption exercise Common Stockindirect: Fairmount Healthcare Fund II LP | +1,600 | $7.80 | $12k | 3,447,413 | Jun 11, 2025 |
| Jun 10, 2025 | Fairmount Funds Management LLC director, owner | MOption exercise Common Stockindirect: Fairmount Healthcare Fund II LP | +12,500 | $12.31 | $154k | 3,459,913 | Jun 11, 2025 |
| Jun 9, 2025 | Fairmount Funds Management LLC director, owner | MOption exercise Stock Option (Right to Buy)derivativeindirect: By: Peter Harwin | -1,600 | $0.00 | $0 | 0 | Jun 11, 2025 |
| Jun 10, 2025 | Fairmount Funds Management LLC director, owner | MOption exercise Stock Option (Right to Buy)derivativeindirect: By: Peter Harwin | -12,500 | $0.00 | $0 | 0 | Jun 11, 2025 |
| Apr 7, 2025 | Jeffrey Robert Ajer director | AGrant or award Stock Option (Right to Buy)derivative | +42,000 | $0.00 | $0 | 42,000 | Apr 9, 2025 |
| Mar 10, 2025 | Christopher W. Cain director | AGrant or award Stock Option (Right to Buy)derivativeindirect: See Footnote | +42,000 | $0.00 | $0 | 42,000 | Mar 12, 2025 |
| Mar 3, 2025 | Thomas W. Beetham Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +225,814 | $0.00 | $0 | 225,814 | Mar 4, 2025 |
| Mar 3, 2025 | Seth Harmon Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +150,407 | $0.00 | $0 | 150,407 | Mar 4, 2025 |
| Mar 3, 2025 | Thomas W. Beetham Chief Operating Officer | AGrant or award Restricted Stock Unitsderivative | +37,636 | $0.00 | $0 | 37,636 | Mar 4, 2025 |
| Mar 3, 2025 | Seth Harmon Chief Financial Officer | AGrant or award Restricted Stock Unitsderivative | +25,068 | $0.00 | $0 | 25,068 | Mar 4, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Jeffrey Robert Ajerdirector
- Thomas W. BeethamChief Operating Officer
- Christopher W. Caindirector
- Fairmount Funds Management LLCdirector, owner
- Sarah Gheuensofficer, director
- Seth HarmonChief Financial Officer
- Tomas Kiselakdirector, owner
- Arlene Morrisdirector
- Jennifer K. Mosesdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.